All In Biotech

Drug Trial Radar · NCT07459452

Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Study to Evaluate the Efficacy and Safety of JYB1904 Injection Combined With Background Therapy in Patients With Perennial Allergic Rhinitis

Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 135 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

135

Planned (sponsor's estimate)

Start

Apr 2026

Primary completion

Oct 2027

Study completion Oct 2028

Sponsor

Lead sponsor
JemincareIndustry
Sponsor type
Industry
First posted
Mar 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase II Trial is Meant to Evaluate the Efficacy, and Safety of JYB1904 Injection in Patients With Perennial Allergic Rhinitis.

Conditions

  • Perennial Allergic Rhinitis

Interventions

  • JYB1904Biological

    Double-blind Induction Period: 150mg -450mg JYB1904 will be administered SC in Day1, Week 8 and Week 16. Open-label Treatment Period: 300mg JYB1904 will be administered SC every 12 weeks (Q12W) from Week 24 to Week 48.

  • JYB1904Biological

    Double-blind Induction Period: 300mg JYB1904 will be administered SC in Day1 and Week 12. Open-label Treatment Period: 300mg JYB1904 will be administered SC Q12W from Week 24 to Week 48.

  • Placebo+JYB1904Biological

    Double-blind Induction Period: Placebo will be administered SC in Day1, Week 8, Week 12 and Week16. Open-label Treatment Period: 300mg JYB1904 will be administered SC Q12W from Week 24 to Week 48.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Reflective Total Nasal Symptom Score (rTNSS) at Week 8 (JYB1904 Q8W vs Placebo) or Week 12 (JYB1904 Q12W vs Placebo)Time frame: baseline, Week 8, Week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.